Vanguard is boosting fees to urge holdout customers to do their own trades online inquirer.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from inquirer.com Daily Mail and Mail on Sunday newspapers.
Gilead Sciences (NASDAQ:GILD – Free Report) had its target price lowered by Wells Fargo & Company from $90.00 to $84.00 in a research report sent to investors on Wednesday morning, Benzinga reports. The firm currently has an equal weight rating on the biopharmaceutical company’s stock. Other equities research analysts have also issued research reports about […]
Atria Investments Inc decreased its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 0.7% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 72,826 shares of the biopharmaceutical company’s stock after selling 485 shares […]
Cornerstone Wealth Management LLC increased its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 4.3% during the 3rd quarter, Holdings Channel reports. The institutional investor owned 9,013 shares of the biopharmaceutical company’s stock after purchasing an additional 373 shares during the quarter. Cornerstone Wealth Management LLC’s holdings in Gilead Sciences were […]